Literature DB >> 22714869

Contribution of rat intestinal metabolism to the xenobiotics clearance.

Mahmud Kajbaf1, Raffaella Ricci, Serenella Zambon, Stefano Fontana.   

Abstract

Michaelis-Menten constants K m and V max values were determined by product formation and substrate depletion at several substrate concentrations of 4-methylumbelliferone using rat intestinal microsomes. K m and V max values determined by measuring product formation were in good agreement with substrate depletion approach. We also investigated hepatic and intestinal in vitro intrinsic clearance (CLint) in the liver and intestinal microsomes and compare with reports in the literature using nine test compounds, atorvastatin, 7-ethoxycoumarin, indomethacin, 4-methylumbelliferone, midazolam, nifedipine, testosterone, terfenadine and verapamil, in rats. CLint was determined from the substrate disappearance rate at 0.1 and 0.5 μM in the rat intestinal and liver microsomes, respectively. These results showed that both the liver and the intestine contributed to the metabolism of these compounds. The intestinal intrinsic clearance values of all these drugs, except for terfenadine in the rat intestinal microsomes, were lower than their hepatic intrinsic clearance per milligram protein, showing that there was an organ difference in metabolism between the liver and intestinal. These results make the evaluation using the intestinal more useful and provide a basis for predicting clearance using intestinal.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22714869     DOI: 10.1007/s13318-012-0098-5

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  39 in total

Review 1.  Molecular and physical mechanisms of first-pass extraction.

Authors:  S D Hall; K E Thummel; P B Watkins; K S Lown; L Z Benet; M F Paine; R R Mayo; D K Turgeon; D G Bailey; R J Fontana; S A Wrighton
Journal:  Drug Metab Dispos       Date:  1999-02       Impact factor: 3.922

2.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.

Authors:  M B Fisher; K Campanale; B L Ackermann; M VandenBranden; S A Wrighton
Journal:  Drug Metab Dispos       Date:  2000-05       Impact factor: 3.922

3.  Intestinal expression and metabolic activity of the CYP3A subfamily in female rats.

Authors:  Tetsuya Aiba; Mariko Yoshinaga; Kazuya Ishida; Yutaka Takehara; Yukiya Hashimoto
Journal:  Biol Pharm Bull       Date:  2005-02       Impact factor: 2.233

4.  In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes.

Authors:  D J Carlile; A J Stevens; E I Ashforth; D Waghela; J B Houston
Journal:  Drug Metab Dispos       Date:  1998-03       Impact factor: 3.922

5.  Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes.

Authors:  Ryan Z Turncliff; Keith A Hoffmaster; J Cory Kalvass; Gary M Pollack; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2006-05-11       Impact factor: 4.030

6.  Lansoprazole increases testosterone metabolism and clearance in male Sprague-Dawley rats: implications for Leydig cell carcinogenesis.

Authors:  Michelle Coulson; G Gordon Gibson; Nick Plant; Tim Hammond; Mark Graham
Journal:  Toxicol Appl Pharmacol       Date:  2003-10-15       Impact factor: 4.219

7.  Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains.

Authors:  A Bruyère; X Declevès; F Bouzom; L Proust; M Martinet; B Walther; Y Parmentier
Journal:  Xenobiotica       Date:  2009-01       Impact factor: 1.908

8.  Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats.

Authors:  Doreen Mitschke; Andreas Reichel; Gert Fricker; Ursula Moenning
Journal:  Drug Metab Dispos       Date:  2008-03-10       Impact factor: 3.922

9.  The human intestinal cytochrome P450 "pie".

Authors:  Mary F Paine; Heather L Hart; Shana S Ludington; Robert L Haining; Allan E Rettie; Darryl C Zeldin
Journal:  Drug Metab Dispos       Date:  2006-02-07       Impact factor: 3.922

10.  In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat.

Authors:  Tsutomu Kotegawa; Bart E Laurijssens; Lisa L Von Moltke; Monette M Cotreau; Michael D Perloff; Karthik Venkatakrishnan; Jill S Warrington; Brian W Granda; Jerold S Harmatz; David J Greenblatt
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

View more
  4 in total

1.  Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats.

Authors:  Jennypher Mudunuru; Chen Ren; David R Taft; Manoj Maniar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-08       Impact factor: 2.441

2.  Synthesis and Pharmacological Evaluation of Novel Silodosin-Based Arylsulfonamide Derivatives as α1A1D-Adrenergic Receptor Antagonist with Potential Uroselective Profile.

Authors:  Vittorio Canale; Aleksandra Rak; Magdalena Kotańska; Joanna Knutelska; Agata Siwek; Marek Bednarski; Leszek Nowiński; Małgorzata Zygmunt; Paulina Koczurkiewicz; Elżbieta Pękala; Jacek Sapa; Paweł Zajdel
Journal:  Molecules       Date:  2018-08-29       Impact factor: 4.411

3.  Comparable Intestinal and Hepatic First-Pass Effect of YL-IPA08 on the Bioavailability and Effective Brain Exposure, a Rapid Anti-PTSD and Anti-Depression Compound.

Authors:  You Gao; Chunmiao Yang; Lingchao Wang; Yanan Xiang; Wenpeng Zhang; Yunfeng Li; Xiaomei Zhuang
Journal:  Front Pharmacol       Date:  2020-11-27       Impact factor: 5.810

4.  Spheroid Size Does not Impact Metabolism of the β-blocker Propranolol in 3D Intestinal Fish Model.

Authors:  Laura M Langan; Stewart F Owen; Maciej Trznadel; Nicholas J F Dodd; Simon K Jackson; Wendy M Purcell; Awadhesh N Jha
Journal:  Front Pharmacol       Date:  2018-08-22       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.